First State Compassion Center
Total Consideration
$11.2M
Purchase-Price Allocation
Goodwill
$8.2M
Intangibles
$570.0K
Deferred Tax Liability
$1.3M
Pro-Forma Combined Entity
Revenue
$161.0M
Net Income
−$17.3M
MARIMED INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-0
Book Value Per Share
$0
Free Cash Flow Per Share
$0
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$0
Return on Equity
-26.7%
Return on Assets
-7.1%
Return on Invested Capital
-1.7%
Debt to Equity
1.52
Current Ratio
1.00
Quick Ratio
0.38
Asset Turnover
0.78
Days Sales Outstanding
20.81
Days Payables Outstanding
52.22
Days Inventory On Hand
131.04
Cash Conversion Cycle
99.64
R&D / Revenue
—
SBC / Revenue
1.2%
Capex / Revenue
0.7%
Working Capital
$223K
Net Current Asset Value
$-79M
Invested Capital
$126M
OCF / Net Income
-0.53
FCF / Net Income
-0.45
Accruals Ratio (Sloan)
-10.9%
Net Debt
$76M
Net Debt / EBITDA
14.38
Interest Coverage
-0.38
Cash Coverage
1.03
Capex Coverage
6.59
Tangible Common Equity
$9M
TCE / Total Assets
4.3%
Goodwill / Total Assets
11.8%
NOPAT
$-2M
Cash ROIC
5.0%
WC / Revenue
0.1%
Capex / D&A
0.14
Reinvestment Rate
254.4%
Asset Growth vs Revenue Growth
-3.5%
Revenue 5Y CAGR
25.7%
EBITDA 5Y CAGR
-20.2%
Book Value 5Y CAGR
43.9%
Stock Price (FY-end)
$0
Market Cap
$37M
P/E Ratio
—
P/S Ratio
0.23
P/B Ratio
0.73
P/TB Ratio
4.17
P/OCF Ratio
4.77
P/FCF Ratio
5.62
Enterprise Value
$113M
EV / EBITDA
21.31
EV / Sales
0.71
EV / FCF
17.27
FCF Yield
17.8%
Shareholder Yield
-5.1%
Capex Yield
3.2%
Operating Leverage
-13.35
Graham Number
—
Shares Variation (YoY)
2.9%
Beta (5Y)
0.45
Cost of Equity
6.7%
Cost of Debt (after tax)
7.8%
WACC
7.5%
ROIC - WACC Spread
-9.1%
52W High
$0
52W Low
$0
Trailing Return 1Y
-21.7%
Trailing Return 5Y
-74.6%
F-Score (Piotroski)
4.00
Z-Score (Altman)
0.02
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
MARIMED INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 46.00% | 16.50% | 12.80% | -4.20% | -9.90% | -5.00% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | -1.00% | 0.90% | 8.20% | -1.20% | 3.40% | -0.70% |
| Valuation Allowance Change | -93.60% | 19.50% | 2.00% | -96.90% | 67.10% | 23.30% |
| Effective Tax Rate | 46.00% | 63.30% | 28.60% | -129.00% | -1.91% | -32.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $2.1M | $16.2M | $5.9M | $9.4M | $8.2M | $3.6M |
| Income Taxes Paid (Cash) | $1.2M | $621.0K | $14.6M | $6.4M | $705.0K | −$713.0K |
MARIMED INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Wellness Compassionate Care Center Inc.
Total Consideration
$5.3M